Quest Diagnostics Incorporated $DGX Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lessened its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 89.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,781 shares of the medical research company’s stock after selling 15,594 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Quest Diagnostics were worth $415,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DGX. Choreo LLC raised its position in shares of Quest Diagnostics by 2.4% in the 3rd quarter. Choreo LLC now owns 2,215 shares of the medical research company’s stock worth $516,000 after acquiring an additional 52 shares in the last quarter. Kingswood Wealth Advisors LLC lifted its stake in shares of Quest Diagnostics by 1.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 3,878 shares of the medical research company’s stock worth $904,000 after purchasing an additional 55 shares during the last quarter. Concurrent Investment Advisors LLC lifted its stake in shares of Quest Diagnostics by 1.2% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 62 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in Quest Diagnostics by 17.9% during the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 67 shares in the last quarter. Finally, North Dakota State Investment Board boosted its position in Quest Diagnostics by 2.1% during the third quarter. North Dakota State Investment Board now owns 3,382 shares of the medical research company’s stock valued at $788,000 after purchasing an additional 68 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DGX has been the topic of several analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $245.00 target price on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Barclays increased their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Weiss Ratings raised shares of Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a research report on Wednesday, October 21st. Robert W. Baird set a $262.00 price target on shares of Quest Diagnostics in a report on Friday, October 23rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $250.00 price objective on shares of Quest Diagnostics in a research report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average price target of $248.70.

Check Out Our Latest Analysis on DGX

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $259.46 on Monday. The business’s fifty day simple moving average is $241.23 and its 200-day simple moving average is $215.58. The company has a market cap of $28.55 billion, a PE ratio of 25.84, a PEG ratio of 2.32 and a beta of 0.54. The company has a current ratio of 1.70, a quick ratio of 1.58 and a debt-to-equity ratio of 0.70. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $262.00.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.87 by $0.13. The firm had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.60 EPS. Analysts expect that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s dividend payout ratio is currently 34.26%.

Quest Diagnostics News Summary

Here’s some of the latest news about DGX:

  • Positive Sentiment: Zacks Research raised several earnings forecasts, including its FY2026 EPS estimate to $11.28 from $11.15 and its Q2 2027 estimate to $3.09 from $2.99. The improved forecasts may support investor confidence, though the FY2026 estimate remains close to the $11.29 consensus.
  • Positive Sentiment: Quest announced a quarterly dividend of $0.86 per share, equivalent to $3.44 annually and a stated yield of about 1.3%. The announcement coincided with DGX reaching a new one-year high. Quest Diagnostics hits a one-year high following dividend announcement
  • Negative Sentiment: Zacks lowered its Q4 2026 EPS estimate to $2.66 from $2.70, partially offsetting the upward revisions for other periods.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Patrick Plewman sold 11,717 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $257.34, for a total value of $3,015,252.78. Following the completion of the sale, the senior vice president directly owned 14,684 shares in the company, valued at approximately $3,778,780.56. This trade represents a 44.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael Prevoznik sold 22,677 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the sale, the senior vice president owned 37,557 shares of the company’s stock, valued at approximately $9,130,482.27. This trade represents a 37.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,702 shares of company stock worth $16,730,269 over the last ninety days. Corporate insiders own 0.88% of the company’s stock.

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.